U.S. Department
of Justice
U.S. v. Teva Pharmaceuticals USA Inc. and Glenmark Pharmaceuticals Inc., USA
Teva Pharmaceuticals USA Inc. was charged with participating in three conspiracies to suppress and eliminate competition by agreeing to fix prices, allocate customers, and rig bids for generic drugs. In the first count, Glenmark was charged along with Teva with knowingly entering into and engaging in a conspiracy to suppress and eliminate competition by agreeing to increase and maintain prices of pravastatin and other generic drugs sold in the United States. The charged conspiracies took place between 2013 and 2015.
For further information:
- Upcoming Public Hearings
- Information on Victim’s Rights
- Related Case U.S. v. Glenmark Pharmaceuticals Inc., USA
For questions about upcoming public hearings or victims’ rights, contact the Victim Hearing Coordinator in the Washington Criminal I Section.
Case Documents:
Deferred Prosecution Agreement [Glenmark Pharmaceuticals] (August 21, 2023)
Deferred Prosecution Agreement [Teva Pharmaceuticals] (August 21, 2023)
Stipulated Protective Order (September 29, 2020)
Second Superseding Indictment (August 25, 2020)
- Bid Rigging
- Customer, Territorial or Market Allocation - Horizontal
- Price Fixing - Horizontal
- Pharmaceutical and Medicine Manufacturing